This article was originally published in The Gray Sheet
Executive SummaryU.S. market launch of Collagraft bone graft matrix strip by Zimmer, which holds domestic and Asian marketing rights, is planned at the American Academy of Orthopaedic Surgeons meeting in New Orleans Feb. 24-28 following recent FDA approval of the product. Shipments are expected to begin "after March 1." The "premixed, freeze-dried" strips will be priced "slightly higher" than the first generation Collagraft implant paste, which requires mixing and refrigeration. Both products are approved for treatment of acute long bone fractures and traumatic osseous defects
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.